Full text is available at the source.
Abstract
Neuroinflammation is linked to the development and progression of various central nervous system diseases.
- Effective treatments for central nervous system diseases are currently limited.
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may help reduce neuroinflammation.
- Preclinical evidence indicates that GLP-1RAs could influence immune cell-related processes.
- The therapeutic potential of GLP-1RAs in central nervous system diseases is suggested by this evidence.
Simplified